Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Reads0
Chats0
TLDR
Five strategies that have the potential to meet either the efficacy and/or the benefit‐to‐risk ratio of a cannabinoid receptor agonist are focused on.Abstract:
Medicines that activate cannabinoid CB(1) and CB(2) receptor are already in the clinic. These are Cesamet (nabilone), Marinol (dronabinol; Delta(9)-tetrahydrocannabinol) and Sativex (Delta(9)-tetrahydrocannabinol with cannabidiol). The first two of these medicines can be prescribed to reduce chemotherapy-induced nausea and vomiting. Marinol can also be prescribed to stimulate appetite, while Sativex is prescribed for the symptomatic relief of neuropathic pain in adults with multiple sclerosis and as an adjunctive analgesic treatment for adult patients with advanced cancer. One challenge now is to identify additional therapeutic targets for cannabinoid receptor agonists, and a number of potential clinical applications for such agonists are mentioned in this review. A second challenge is to develop strategies that will improve the efficacy and/or the benefit-to-risk ratio of a cannabinoid receptor agonist. This review focuses on five strategies that have the potential to meet either or both of these objectives. These are strategies that involve: (i) targeting cannabinoid receptors located outside the blood-brain barrier; (ii) targeting cannabinoid receptors expressed by a particular tissue; (iii) targeting up-regulated cannabinoid receptors; (iv) targeting cannabinoid CB(2) receptors; or (v) 'multi-targeting'. Preclinical data that justify additional research directed at evaluating the clinical importance of each of these strategies are also discussed.read more
Citations
More filters
Journal ArticleDOI
The Endocannabinoid System and the Brain
TL;DR: Research on the actions of the endocannabinoid system on anxiety, depression, neurogenesis, reward, cognition, learning, and memory, and the effects are at times biphasic--lower doses causing effects opposite to those seen at high doses.
Journal ArticleDOI
Proof of concept trial of dronabinol in obstructive sleep apnea
TL;DR: Dronabinol treatment is safe and well-tolerated in OSA patients at doses of 2.5–10 mg daily and significantly reduces AHI in the short-term and should be confirmed in a larger study in order to identify sub-populations with OSA that may benefit from cannabimimetic pharmacologic therapy.
Journal ArticleDOI
Cannabinoids and the Gut: New Developments and Emerging Concepts
Angelo A. Izzo,Keith A. Sharkey +1 more
TL;DR: Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric infections and inflammatory conditions to disorders of motility, emesis and abdominal pain, with recent data on genetic mutations in the endocannabinoid system in GI disease highlighted.
Journal ArticleDOI
Cannabis, a complex plant: different compounds and different effects on individuals.
TL;DR: An overview of the biochemical basis of cannabis research is provided by examining the different effects of the two main compounds of the plant and the endocannabinoid system, and available information on the possible factors explaining variation of its effects upon different individuals is reviewed.
Journal ArticleDOI
Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials
Mary E. Lynch,Fiona Campbell +1 more
TL;DR: There is evidence that cannabinoids are safe and modestly effective in neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis and the context of the need for additional treatments for chronic pain is reviewed.
References
More filters
Journal ArticleDOI
Isolation and structure of a brain constituent that binds to the cannabinoid receptor
William A. Devane,Lumir Hanus,Aviva Breuer,Roger G. Pertwee,Lesley A. Stevenson,Graeme Griffin,Dan Gibson,Asher Mandelbaum,A. Etinger,Raphael Mechoulam +9 more
TL;DR: In this article, an arachidonylethanthanolamide (anandamide) was identified in a screen for endogenous ligands for the cannabinoid receptor and its structure was determined by mass spectrometry and nuclear magnetic resonance spectroscopy and confirmed by synthesis.
Journal ArticleDOI
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Raphael Mechoulam,Shimon Ben-Shabat,Lumir Hanus,Moshe Ligumsky,Norbert E. Kaminski,Anthony R. Schatz,Asher Gopher,Shlomo Almog,Billy R. Martin,David R. Compton,Roger G. Pertwee,Graeme Griffin,Michael Bayewitch,Jacob Barg,Zvi Vogel +14 more
TL;DR: Upon intravenous administration to mice, 2-Ara-Gl caused the typical tetrad of effects produced by THC: antinociception, immobility, reduction of spontaneous activity, and lowering of the rectal temperature.
Journal ArticleDOI
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Allyn C. Howlett,Francis Barth,Tom I. Bonner,Guy A. Cabral,Pierre Casellas,William A. Devane,Christian C. Felder,Miles Herkenham,Ken Mackie,Billy R. Martin,Raphael Mechoulam,Roger G. Pertwee +11 more
TL;DR: It is considered premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification, because pharmacological evidence for the existence of additional types of cannabinoid receptor is emerging and other kinds of supporting evidence are still lacking.
Journal ArticleDOI
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Takayuki Sugiura,Sachiko Kondo,Akihiro Sukagawa,Shinji Nakane,A. Shinoda,K. Itoh,Atsushi Yamashita,Keizo Waku +7 more
TL;DR: 2-Arachidonoylglycerol was shown to bind appreciably to the cannabinoid receptor in competitive inhibition experiments and may be an endogenous cannabinoid receptor ligand in the brain.
Journal ArticleDOI
Guide to Receptors and Channels (GRAC), 3rd edition.
TL;DR: The Fifth Edition of the 'Guide to Receptors and Channels' is a compilation of the major pharmacological targets divided into seven sections: G protein-coupled receptors, ligand-gated ion channels, ion channel, catalytic receptors, nuclear receptors, transporters and enzymes.